Microbot Medical Inc. (MBOT)
| Market Cap | 16.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.03M |
| Shares Out | 7.89M |
| EPS (ttm) | -1.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,121 |
| Open | 2.27 |
| Previous Close | 2.25 |
| Day's Range | 2.12 - 2.27 |
| 52-Week Range | 2.12 - 6.77 |
| Beta | 3.24 |
| Analysts | Buy |
| Price Target | 20.40 (+853.27%) |
| Earnings Date | Mar 30, 2023 |
About MBOT
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 paten... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MBOT stock is "Buy." The 12-month stock price forecast is $20.4, which is an increase of 853.27% from the latest price.
News
Microbot Medical Launches Presence in the United Kingdom as Highly Accomplished Consultant Interventional Radiologist Professor Mark W. Little Joins its Scientific Advisory Board as Efforts to Commercialize the LIBERTY® Robotic System Continue to Accelerate
Internationally Recognized Academic Leader Awarded the National Institute for Health Research (NIHR) Research Rising Star Award, and Cardiovascular and Interventional Radiology (CVIR) Editors Medal In...
Microbot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board
Internationally Recognized and Awarded Interventional Radiologist Enhances Depth of Expertise as the LIBERTY® Robotic System Races Towards Regularity and Commercialization Objectives Internationally R...
Microbot Medical's Chief Medical Officer Dr. Eyal Morag to Highlight Performance, Safety and Usability Benefits of the LIBERTY® Robotic System During Podium Presentation at Prestigious Robotics Conference
HINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced...
Microbot Medical Meeting with Key Opinion Leaders, Hospital Administrators, and Potential Strategic and Commercial Partners at the Society of Interventional Radiologist Annual Meeting
Continues to Raise Awareness of the LIBERTY® Robotic System Ahead of Commercialization Plans Continues to Raise Awareness of the LIBERTY® Robotic System Ahead of Commercialization Plans
Microbot Medical Welcomes Distinguished Interventional Cardiologist and Early Adopter of Endovascular Robotics to its Next “Access-Ability Live by MBOT” Webinar Series
Dr. Giora Weisz, a Practicing Interventional Cardiologist and Clinical Researcher who was One of the Early Users of Robotic-Enhanced Coronary Interventions, as well as Navigation and Positioning Techn...
Microbot Medical Announces MedTech Industry Veteran Joe Mullings will Moderate the Next ‘Access-Ability Live by MBOT' Webinar
Panel of Proven Medical Device Entrepreneurs and Surgical Robotics Pioneers Will Share Their Personal Experiences of Taking Innovative New Technologies from Development to Commercialization
Microbot Medical Inc. (MBOT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Microbot Medical Inc. (MBOT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen...
Microbot Medical Announces the Participation of a Key Opinion Leader in the Endovascular Robotics Space at the Next “Access-Ability Live by MBOT” Webinar Series
The Webinar, Which is Suitable to All Stakeholders Interested in the Future of Endovascular Robotics, Will be Held on Wednesday, December 21, 2022, at 1:00pm ET
Microbot Medical's Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel
Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress
Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space
Th e “ Access-Ability Live” by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience
Microbot Medical Receives Additional Patent Allowance in Israel for the LIBERTY® Robotic System
Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology Corresponding Application Previously Granted in the U.S. a...
Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe's Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board
Growing SAB Roster Includes 11 KOLs from Across the U.S. , Europe, and Israel
Microbot Medical Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single institutiona...
Microbot Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the purc...
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY® Robotic System
HINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY® Robotic System...
Microbot Medical Completes GLP Animal Study for the LIBERTY® Robotic System
HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic Syste...
Microbot Medical Receives Patent Allowance in Israel for the LIBERTY® Robotic System
Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the Technology Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniquenes...
Microbot Medical Strengthens LIBERTY® Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices
Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chro...
Microbot Medical Announce Strategic Addition to Scientific Advisory Board Appointment
Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience
Microbot Medical Enhances its Scientific Advisory Board (SAB) with its Newest Member Dr. Vincent Vidal
Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY® Robotic System Prominent France based interventional ...
Microbot Medical to Review Recent Progress During H.C. Wainwright's 24th Annual Global Investment Conference
Company Continues to Achieve Primary Objectives for its LIBERTY® Robotic System in 2022 Company Continues to Achieve Primary Objectives for its LIBERTY® Robotic System in 2022
Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY® Robotic System
GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the E...
Microbot Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke
A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization
Microbot Medical Confirms GLP Pre-Clinical Trial is on Track to Commence Later this Month
HINGHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark su...
Microbot Medical to Present the Self-Cleaning Shunt at the 16th Asian Australasian Congress of Neurological Surgeons
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company's Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Cong...